Cx Institutional Biomarin Pharmaceutical Inc Transaction History

Cx Institutional

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 18, 2022	SELL	$71.72 - $91.47 $717 - $914	-10 Closed	0 $0
Q2 2021 Aug 04, 2021	BUY	$75.51 - $84.79 $755 - $847	10 New	10 $1,000
Q1 2021 Apr 15, 2021	SELL	$74.73 - $90.69 $1,270 - $1,541	-17 Closed	0 $0
Q4 2020 Jan 12, 2021	SELL	$72.61 - $90.2 $217 - $270	-3 Reduced 15.0%	17 $1,000
Q3 2020 Oct 13, 2020	BUY	$71.87 - $131.03 $1,437 - $2,620	20 New	20 $2,000
Q3 2019 Oct 10, 2019	SELL	$67.4 - $85.11 $1,819 - $2,297	-27 Closed	0 $0
Q2 2019 Jul 17, 2019	SELL	$80.35 - $93.9 $1,928 - $2,253	-24 Reduced 47.06%	27 $2,000
Q1 2019 Apr 03, 2019	BUY	$84.2 - $98.62 $4,294 - $5,029	51 New	51 $5,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Cx Institutional, based on Form 13F filings with the SEC.

Stay updated on Cx Institutional with notifications on news.